Sanofi's shares declined 1.6% to trade at €78.62 today after the French drugmaker released its Q2 2026 financial results. The report included a headline revenue beat and an upward revision to full-year guidance, but several underwhelming elements in the quarter led investors to pare positions.
The company posted quarterly revenue of €11.6 billion, ahead of the €11.2 billion consensus. Management raised its full-year 2026 revenue growth outlook to approximately 10% at constant exchange rates, increasing the prior target of high single-digit growth.
Despite those positive top-line figures, pockets of weakness emerged. Vaccine sales totaled €1.15 billion, below the €1.20 billion consensus, underscoring continued softness in that business. In addition, the earlier decision to abandon global regulatory filings for amlitelimab in atopic dermatitis remained a dampening factor for sentiment around Sanofi's pipeline.
Offsetting some of the concerns, the company's flagship biologic Dupixent delivered €5.15 billion in sales for the quarter, coming in 16% ahead of consensus estimates and continuing to serve as Sanofi's principal growth driver.
Market conditions offered little relief. The U.S. Federal Reserve left interest rates unchanged on July 29 amid renewed inflation worries, a move that coincided with a sharp rise in long-dated bond yields and a cautious tone across global equity markets. At the same time, the CAC 40 - Sanofi's domestic benchmark - has experienced volatility through July amid U.S. tariff tensions and geopolitical uncertainty, limiting sector-wide support.
Taken together, the market reaction appears to reflect a recalibration following a period when investors had rewarded Sanofi's recent operational execution. While the stronger-than-expected Dupixent performance and the higher guidance point to constructive fundamentals, the vaccine shortfall and lingering pipeline concerns prompted profit-taking in a risk-averse environment.
The stock now trades well below its 52-week high of €91.15, illustrating how the combination of single-line misses and macro caution can outweigh headline beats in the near term.